EEG system Zeto ONE has achieved 510(k) clearance from the Food and Drug Administration (FDA), as announced by U.S.-based medical device manufacturer Zeto. This innovative medical device is designed for use in various environments, including hospitals, homes, ambulances, and air transport settings.
The Zeto ONE medical device features a headset equipped with 21 soft-tip electrodes positioned according to the internationally recognized 10-20 EEG system, which standardizes electrode placement. This design ensures the system is user-friendly, requiring minimal training for operation. The headset also captures patient video and audio, and includes live AI-enabled seizure notifications, enhancing its functionality.
One of the standout features of the Zeto ONE medical device is its integration with the Zeto Cloud platform. This cloud-based system streams data in real-time, allowing neurologists to perform live remote interpretations. Additionally, the Zeto Cloud supports comprehensive EEG platform capabilities, including workflow management, patient scheduling, and report generation. EEG is a crucial medical test used to measure the brain’s electrical activity. It aids in diagnosing various conditions, such as epilepsy, sleep disorders, and brain tumors. The Zeto ONE system’s ability to deliver high-quality EEG data in diverse settings makes it a significant advancement in the field of neurology.
Medical Device Innovator Zeto Secures FDA Clearance for Versatile Zeto ONE EEG System
Founded in 2014 and based in Santa Clara, Zeto has been at the forefront of EEG technology innovation. In 2020, the company raised $7.3 million in Series A funding led by Seraph Group, with participation from Aphelion Capital, SV Tech Ventures, and Shangbay Capital. This funding has been instrumental in advancing Zeto’s technology and expanding its product offerings.
The FDA’s clearance of the Zeto ONE medical device follows the company’s earlier success with its first wireless, dry-electrode EEG headset, WR19, which was approved for clinical use in 2020. The WR19 underwent three clinical studies involving 50 subjects, demonstrating signal quality on par with FDA-cleared traditional EEG systems. These studies included simultaneous recordings with WR19 and Clinical EEG (cEEG) electrodes placed about 1cm-2cm apart, confirming the reliability and accuracy of Zeto’s technology.
The Zeto ONE system’s versatility extends beyond traditional hospital settings, making it suitable for home use and emergency situations in ambulances and air transport. This adaptability addresses the growing need for accessible and reliable neurological monitoring across different environments, providing a comprehensive solution for patient care. The integration of AI technology in the Zeto ONE medical device further enhances its utility. The AI-enabled seizure notifications provide immediate alerts, enabling timely intervention and improving patient outcomes. This feature, combined with the system’s remote interpretation capabilities, supports efficient and effective patient management.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.